Agenix

11 Durbell St., Acacia Ridge QLD 4110 AUSTRALIA

AGENIX Limited is a leading edge biotechnology company with operations in two niche businesses: AGEN Biomedical Limited and Milton Pharmaceuticals Pty Ltd, and an investment in PhytoProtein Pte Ltd. AGEN BIOMEDICAL LIMITED. AGEN specialises in advanced medical diagnosis of human and animal diseases and is well positioned as a world-class thrombosis and blood clot specialist. Building on existing technology platforms, AGEN is continuously investing in research and development. AGEN is in the process of commercialising a breakthrough technology in blood clot imaging called ThromboView®. MILTON PHARMACEUTICALS. Milton specialises in the manufacture and distribution of biopharmaceutical products. With its established distribution network in Australia, Milton has more than 60% market share in the domestic galenicals market. The company's recent purchase of the Milton Infant Hygeine range from Proctor and Gamble places the company at the forefront of the infant hygeine market. PHYTOPROTEIN BIOTECH. PhytoProtein manufactures complex immunogenic proteins using plant-cell based expresssion systems. Development of the technology will first concentrate on production of antigens (immunogenic proteins) for use in diagnostic kits, and then extend to the production of human and animal vaccines.

Benitec Australia Limited

PO Box 4193, St Lucia QLD 4067 AUSTRALIA

Benitec has proprietary IP in gene silencing technology based on RNA interference (RNAi). This revolutionary technology provides a natural, precise and proven process for silencing any gene in any cell of any multicellular organism. Benitec's universal technology platform accelerates and expands our customers' capacity for target validation and gene discovery. It also offers potential for development of therapeutic applications for catastrophic diseases including cancers, autoimmune dysfunctions and viral infections. In addition, Benitec creates value for agbiotech companies by accelerating delivery of targets for pesticides and new products for plant protection, enhanced food quality and animal health.

Novogen
(NVGN) 0.50

140 Wicks Road, NORTH RYDE NSW 2113, AUSTRALIA

The Company's main focus has been on the development of prescription drugs based on the isoflavonoid technology platform. However, one of the special features of this platform is that it lends itself to be used to develop non-prescription products. In 1995, Novogen took the decision to bring a range of consumer (non-prescription) health products to market while it was continuing to develop its prescription drugs.

Prana Biotechnology Ltd

Level 2, 369 Royal Parade, Parkville VIC 3052 Australia

The development of Prana's library of Metal-Protein Attenuating Compounds ('MPACs') commenced with the observation that Prana's first proof-of-concept MPAC - clioquinol ('PBT1'), abolished Alzheimer's-like changes in the brains of genetically engineered mice. Subsequent work demonstrated a significant reduction in cognitive decline in a pilot phase IIa study in Alzheimer's patients receiving PBT1. Due to an unrectifiable manufacturing impurity, PBT1 was retired and immediately succeeded by an improved and novel MPAC – 'PBT2' , the leading candidate to arise out of Prana's unique drug discovery platform. PBT2, while sharing a similar mechanism of action to PBT1, demonstrates superior technical and medicinal properties.

Progen Industries Ltd
(PGLA.PK) 0.25

16 Benson St, Toowong, Queensland 4066 Australia

Progen has built a focus and strength in anti-cancer drug discovery and development. The company's researchers and collaborators have gained a strong intimate understanding around the role of heparan sulfate, a complex sugar, in cancer disease processes and is developing a small-molecule drug development program in this area. PI-88 is the first product from this research focus and is showing promise from clinical trials conducted to date. The drug discovery program's main objective is to deliver promising drug candidates into human trials for pipeline growth.

Proteome Systems

Locked Bag 2073, North Ryde, NSW, Australia 2113 6 Gill Street, Woburn, MA, 01801

Proteome Systems Limited is an Australian based biotechnology company which discovers and develops diagnostic and therapeutic products. The Company has extensive expertise in the discovery and development of protein biomarkers. Our lead programmes for biomarker discovery and development are Tuberculosis, Prostate Cancer and Huntington’s Disease. We have developed a rapid and quantitative diagnostic device platform known as DiagnostIQ, to facilitate the commercialisation of our biomarkers for diagnostic applications. An extensive patent portfolio of small molecule drug compounds entering clinical development with potential applications in several disease areas.